Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
Also see the archival list of Science's Compass: Enhanced Perspectives
MICROBIOLOGY: Enhanced: TB--A New Target, a New Drug
Stewart T. Cole and Pedro M. Alzari
Tuberculosis (TB) kills 2 million people annually worldwide and imposes huge costs on communities, particularly those in developing countries. Yet no new drugs for TB have been discovered in the past 40 years. This is set to change, as Cole and Alzari report in their Perspective, with the discovery of a diarylquinoline compound that is highly active against a broad range of mycobacterial species including both the drug-sensitive and drug-resistant forms of M. tuberculosis, the bacterium that causes TB (Andries et al.).
The authors are in the Génétique Moléculaire Bactérienne and Biochimie Structurale Units, Institut Pasteur, Paris 75724 Cedex 15, France. E-mail: stcole{at}pasteur.fr, alzari@pasteur.fr
The editors suggest the following Related Resources on Science sites:
In Science Magazine
RESEARCH ARTICLES
Koen Andries, Peter Verhasselt, Jerome Guillemont, Hinrich W. H. Göhlmann, Jean-Marc Neefs, Hans Winkler, Jef Van Gestel, Philip Timmerman, Min Zhu, Ennis Lee, Peter Williams, Didier de Chaffoy, Emma Huitric, Sven Hoffner, Emmanuelle Cambau, Chantal Truffot-Pernot, Nacer Lounis, and Vincent Jarlier (14 January 2005) Science307 (5707), 223.
[DOI: 10.1126/science.1106753] |Abstract »|Full Text »|PDF »|Supporting Online Material »
EDITORIAL
Christopher Dye (14 January 2005) Science307 (5707), 181.
[DOI: 10.1126/science.1109116] |Summary »|PDF »
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
The Diagnosis and Therapy of Tuberculosis During the Past 100 Years.
